Revised guidelines for amyloid and tau positron emission tomography for Alzheimer’s disease and dementia state these tests ...

D imaging and organoid models are revolutionizing dementia research, offering deeper insights into disease mechanisms and ...

Several companies are developing PET amyloid imaging agents labeled with [18 F] that could be transported long distances to hospitals and clinics. For this partially manufacturer-funded study ...

PET imaging uses a radioactive drug (tracer ... identified a radiotracer that could be used to detect the presence of amyloid protein plaques in the brain, which are among the markers for ...

Figure 1: Imaging of amyloid-β deposits in the live mouse. Figure 3: In vivo imaging of amyloid-β deposits in 20-month-old homozygous PDAPP mice. Immunostaining with biotinylated or ...

By increasing Neuraceq® manufacturing capabilities in Somerset, NJ, in partnership with SOFIE, we are strengthening our efforts to meet the growing demand for amyloid PET imaging. This initiative ...

In pursuit of this vision, subsidiaries of EB have provided the best-in-class Tau and Amyloid PET imaging biomarkers, MK-6240 and NAV-4694, to our partners to enable their research efforts.

Similarly, there were no significant effects on Alzheimer’s fluid biomarkers favoring AL002, and amyloid PET imaging demonstrated no treatment-related reduction of brain amyloid levels.

Life Molecular Imaging (LMI), an international pharmaceutical company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging, and SOFIE Biosciences (SOFIE), a ...